Camelia Savulescu1, Silvia Jiménez-Jorge2, Concha Delgado-Sanz2, Salvador de Mateo2, Francisco Pozo3, Inmaculada Casas3, Amparo Larrauri2. 1. Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos No. 5, 28029 Madrid, Spain. Electronic address: camisav@gmail.com. 2. Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos No. 5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. 3. Institute of Health Carlos III, Influenza Reference Laboratory, WHO National Influenza Centre, National Centre for Microbiology, 28220 Majadahonda, Madrid, Spain.
Abstract
BACKGROUND: We used data provided by the Spanish influenza surveillance system to measure seasonal influenza vaccine effectiveness (VE) against medically attended cases, laboratory confirmed with the predominately circulating influenza virus over eight seasons (2003-2011). METHODS: Using the test-negative case-control design, we compared the vaccination status of swabbed influenza-like illnesses (ILI) patients who were laboratory confirmed with predominantly circulating influenza strain in the season (cases) to that of ILI patients testing negative for any influenza (controls). Data on age, sex, vaccination status and laboratory results were available for all seasons. We used logistic regression to calculate adjusted influenza VE for age, week of swabbing, Spanish region and season. We calculated the influenza VE by each season and pooling the seasons with the same predominant type/subtype. RESULTS: Overall influenza VE against infection with A(H3N2) subtype (four seasons) was 31 (95% confidence interval (CI):10; 48). For seasonal influenza A(H1N1) (two seasons), the effectiveness was 86% (95% CI: 65; 94). Against B infection (three seasons), influenza VE was 47% (95% CI: 27; 62). CONCLUSIONS: The Spanish influenza surveillance system allowed estimating influenza VE in the studied seasons for the predominant strain. Strengthening the influenza surveillance will result in more precise VE estimates for decision making.
BACKGROUND: We used data provided by the Spanish influenza surveillance system to measure seasonal influenza vaccine effectiveness (VE) against medically attended cases, laboratory confirmed with the predominately circulating influenza virus over eight seasons (2003-2011). METHODS: Using the test-negative case-control design, we compared the vaccination status of swabbed influenza-like illnesses (ILI) patients who were laboratory confirmed with predominantly circulating influenza strain in the season (cases) to that of ILI patients testing negative for any influenza (controls). Data on age, sex, vaccination status and laboratory results were available for all seasons. We used logistic regression to calculate adjusted influenza VE for age, week of swabbing, Spanish region and season. We calculated the influenza VE by each season and pooling the seasons with the same predominant type/subtype. RESULTS: Overall influenza VE against infection with A(H3N2) subtype (four seasons) was 31 (95% confidence interval (CI):10; 48). For seasonal influenza A(H1N1) (two seasons), the effectiveness was 86% (95% CI: 65; 94). Against B infection (three seasons), influenza VE was 47% (95% CI: 27; 62). CONCLUSIONS: The Spanish influenza surveillance system allowed estimating influenza VE in the studied seasons for the predominant strain. Strengthening the influenza surveillance will result in more precise VE estimates for decision making.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Joon Young Song; Jin Soo Lee; Seong-Heon Wie; Hyo Youl Kim; Jacob Lee; Yu Bin Seo; Hye Won Jeong; Shin Woo Kim; Sun Hee Lee; Kyung-Hwa Park; Ji Yun Noh; Won Suk Choi; Hee Jin Cheong; Woo Joo Kim Journal: Clin Vaccine Immunol Date: 2014-12-24
Authors: George N Okoli; Florentin Racovitan; Christiaan H Righolt; Salaheddin M Mahmud Journal: Open Forum Infect Dis Date: 2020-05-21 Impact factor: 3.835
Authors: Maryam Darvishian; Frederika Dijkstra; Eva van Doorn; Maarten J Bijlsma; Gé A Donker; Marit M A de Lange; Laura M Cadenau; Eelko Hak; Adam Meijer Journal: PLoS One Date: 2017-01-09 Impact factor: 3.240
Authors: George N Okoli; Florentin Racovitan; Tiba Abdulwahid; Syed K Hyder; Louise Lansbury; Christiaan H Righolt; Salaheddin M Mahmud; Jonathan S Nguyen-Van-Tam Journal: Open Forum Infect Dis Date: 2021-02-05 Impact factor: 3.835